Related Experiment Video
Updated: May 6, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Oncogenic MAGEA4 directs neuroendocrine differentiation and survival in prostate cancer cells through the
Maresha Ramakrishna1,2, Teja Nallavolu1,2, Ramesh Ummanni3,4
1Department of Applied Biology, CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Tarnaka, Uppal Road, Hyderabad - 007, Hyderabad, India.
Background:
Neuroendocrine prostate cancer (NEPC) is a highly aggressive and therapy-resistant subtype of prostate cancer (PCa) that emerges following the androgen receptor (AR) targeted therapies. Identification of potential molecular drivers governing neuroendocrine differentiation (NED) and survival is critical for developing therapeutic strategies. Cancer-testis antigens of the Melanoma-associated antigen family (MAGE) are the emerging players of oncogenic regulators. However, their role in NEPC remains unexplored.
Methods:
Proteomic and transcriptomic analyses were performed to identify differential expression of target proteins in NEPC. Functional characterization of MAGEA4 was performed using stable overexpression, siRNA-mediated knockdown in androgen-dependent/independent, and NEPC cell lines. For target validation, neuroendocrine markers, morphological characteristics, apoptotic signaling, oxidative pathways, and cell survival were evaluated using molecular, biochemical, and pharmacological approaches targeting SIRT1, p53 acetylation, BCL-2/BCL-XL and NRF2.
Results:
MAGEA4 was upregulated in NEPC cells and in advanced prostate cancer tissues. Overexpression of MAGEA4 induced neuroendocrine differentiation, promoted androgen-independent survival, and conferred resistance to apoptosis. Furthermore, MAGEA4 upregulated SIRT1 activity, which deacetylated p53, thereby suppressing pro-apoptotic signaling. Additionally, MAGEA4 enhanced the oxidative stress resistance through activation of the SIRT1/PGC-1α/NRF2 axis, suggesting a role in retaining the NED phenotype. In MAGEA4-positive cells, inhibition of BCL-2 and/or NRF2 attenuated the neuroendocrine characteristics, suggesting therapeutic vulnerability.
Conclusion:
These findings highlight that MAGEA4 may contribute to neuroendocrine differentiation and survival in prostate cancer cells, and may represent a potential therapeutic vulnerability in aggressive prostate cancers.
Insights
Melanoma-associated antigen family 4 (MAGEA4) promotes neuroendocrine prostate cancer (NEPC) development and survival by upregulating SIRT1. Targeting MAGEA4 or its downstream pathways offers a potential therapeutic strategy for aggressive prostate cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Neuroendocrine prostate cancer (NEPC) is an aggressive, therapy-resistant subtype of prostate cancer (PCa).
- Identifying molecular drivers of NEPC and survival is crucial for new therapeutic strategies.
- Melanoma-associated antigen family (MAGE) proteins are emerging oncogenic regulators, but their role in NEPC is unknown.
Purpose of the Study:
- To investigate the role of MAGE family proteins, specifically MAGEA4, in the development and progression of NEPC.
- To elucidate the molecular mechanisms by which MAGEA4 influences NEPC cell differentiation, survival, and therapeutic resistance.
Main Methods:
- Proteomic and transcriptomic analyses to identify differentially expressed proteins in NEPC.
- Functional studies involving MAGEA4 overexpression and knockdown in various prostate cancer cell lines.
- Evaluation of neuroendocrine markers, apoptosis, oxidative stress pathways (SIRT1, p53, NRF2), and cell survival.
Main Results:
- MAGEA4 is upregulated in NEPC cells and advanced prostate cancer tissues.
- MAGEA4 overexpression drives neuroendocrine differentiation, androgen-independent survival, and apoptosis resistance.
- MAGEA4 upregulates SIRT1, leading to p53 deacetylation and enhanced oxidative stress resistance via the SIRT1/PGC-1α/NRF2 axis.
- Inhibition of BCL-2 and/or NRF2 in MAGEA4-positive cells reduced NEPC characteristics, indicating therapeutic vulnerability.
Conclusions:
- MAGEA4 plays a significant role in promoting neuroendocrine differentiation and survival in prostate cancer.
- MAGEA4 represents a potential therapeutic target for aggressive prostate cancers, particularly those exhibiting NEPC features.
- Targeting MAGEA4-associated pathways like SIRT1/NRF2 may offer novel treatment strategies for NEPC.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:23Abnormal Proliferation
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22PI3K/mTOR/AKT Signaling Pathway
01:06Induced Pluripotent Stem Cells
Somatic...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...